Trius Confident After Phase II Results For Skin Infections, Including MRSA

Trius Therapeutics is headed into Phase III for its lead antibiotic candidate torezolid (TR-701) with an important advantage over other sponsors that have tried for a complicated skin and skin structure claim in the past year: Trius has a clear sense of the outcome FDA now expects to see in a noninferiority study.